COVID-19 Clinical Guidelines–Special Populations

If we can assist your organization in the battle against COVID-19, whether or not you are a current member, please contact us today at clientservices@ecri.org.

Clinical practice guideline for solid organ donation and transplantation during the COVID-19 pandemic. Version 1.0

Date: 2021 Oct
Developer: Canadian Blood Services/Canadian Donation and Transplantation Research Program/Canadian Society of Transplantation/Peter Morris Centre for Evidence in Transplantation

Guideline Focus
Organ donation and transplantation (ODT) activity during the COVID-19 pandemic

Patient Population
Adult and pediatric transplant recipients and donors with known or suspected COVID-19

Major Interventions

  • Guidance on screening of patients who are potential deceased organ donors, including COVID-19-positive donors, polymerase chain reaction (PCR) methods and repeat tests, computed tomography (CT) scans, and use of antibodies
  • Guidance on recipient treatment and prevention in the setting of COVID-19, including modifications to induction immunosuppression, temporary and preemptive adjustment of immunosuppression, proceeding with transplantation, and use of prophylaxis and anti-COVID-19 therapy

Cardio‐oncology care in the era of the coronavirus disease 2019 (COVID‐19) pandemic: an International Cardio‐Oncology Society (ICOS) statement

Date: 2020 Nov
Developer: International Cardio‐Oncology Society (ICOS)

Guideline Focus
Cardiac safety among patients with cancer during and after this COVID-19 pandemic

Patient Population
Patients with cancer and cardiovascular disease

Major Interventions

  • Infection prevention measures, including personal protection equipment (PPE)
  • Role of virtual consultation and considerations for cardiovascular surveillance
  • Prevention and management of cardiac complications, including for specific medication regimens
  • Considerations for radiation therapy
  • Use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) during COVID-19
  • Considerations for cancer therapies with risk of arrhythmia, QT prolongation, and thromboembolism

EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic

Date: 2021 Jan
Developer: European Academy of Neurology (EAN)

Guideline Focus
Management of neurological diseases during the COVID-19 pandemic

Patient Population
Patients with neurological diseases during the COVID-19 pandemic

Major Interventions

  • Organization of care interventions
  • Guidance on management and therapy of neurological symptoms and neurological complications
  • Considerations for patients with chronic neurological conditions

For access to additional guidelines, check out and search the entire ECRI Guidelines Trust® (EGT), a repository of objective, evidence-based clinical practice guidelines.

Return to the ECRI COVID-19 Resource Center